JP2022546609A5 - - Google Patents

Info

Publication number
JP2022546609A5
JP2022546609A5 JP2022514998A JP2022514998A JP2022546609A5 JP 2022546609 A5 JP2022546609 A5 JP 2022546609A5 JP 2022514998 A JP2022514998 A JP 2022514998A JP 2022514998 A JP2022514998 A JP 2022514998A JP 2022546609 A5 JP2022546609 A5 JP 2022546609A5
Authority
JP
Japan
Application number
JP2022514998A
Other languages
Japanese (ja)
Other versions
JPWO2021046549A5 (https=
JP2022546609A (ja
JP7667139B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/049772 external-priority patent/WO2021046549A1/en
Publication of JP2022546609A publication Critical patent/JP2022546609A/ja
Publication of JPWO2021046549A5 publication Critical patent/JPWO2021046549A5/ja
Publication of JP2022546609A5 publication Critical patent/JP2022546609A5/ja
Priority to JP2025065195A priority Critical patent/JP2025108559A/ja
Application granted granted Critical
Publication of JP7667139B2 publication Critical patent/JP7667139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022514998A 2019-09-06 2020-09-08 ウイルス感染症の治療のための組成物及び方法 Active JP7667139B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025065195A JP2025108559A (ja) 2019-09-06 2025-04-10 ウイルス感染症の治療のための組成物及び方法

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201962897036P 2019-09-06 2019-09-06
US62/897,036 2019-09-06
US201962941405P 2019-11-27 2019-11-27
US62/941,405 2019-11-27
US201962948143P 2019-12-13 2019-12-13
US62/948,143 2019-12-13
US202062959857P 2020-01-10 2020-01-10
US62/959,857 2020-01-10
US202062966500P 2020-01-27 2020-01-27
US62/966,500 2020-01-27
US202062970491P 2020-02-05 2020-02-05
US62/970,491 2020-02-05
US202062984705P 2020-03-03 2020-03-03
US62/984,705 2020-03-03
US202062988304P 2020-03-11 2020-03-11
US62/988,304 2020-03-11
US202063032488P 2020-05-29 2020-05-29
US63/032,488 2020-05-29
US202063062377P 2020-08-06 2020-08-06
US63/062,377 2020-08-06
PCT/US2020/049772 WO2021046549A1 (en) 2019-09-06 2020-09-08 Compositions and methods for the treatment of viral infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025065195A Division JP2025108559A (ja) 2019-09-06 2025-04-10 ウイルス感染症の治療のための組成物及び方法

Publications (4)

Publication Number Publication Date
JP2022546609A JP2022546609A (ja) 2022-11-04
JPWO2021046549A5 JPWO2021046549A5 (https=) 2023-09-15
JP2022546609A5 true JP2022546609A5 (https=) 2023-09-15
JP7667139B2 JP7667139B2 (ja) 2025-04-22

Family

ID=74852729

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022514998A Active JP7667139B2 (ja) 2019-09-06 2020-09-08 ウイルス感染症の治療のための組成物及び方法
JP2025065195A Pending JP2025108559A (ja) 2019-09-06 2025-04-10 ウイルス感染症の治療のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025065195A Pending JP2025108559A (ja) 2019-09-06 2025-04-10 ウイルス感染症の治療のための組成物及び方法

Country Status (18)

Country Link
US (4) US20210220478A1 (https=)
EP (1) EP4025256A4 (https=)
JP (2) JP7667139B2 (https=)
KR (1) KR20220088527A (https=)
CN (2) CN114980933B (https=)
AU (2) AU2020342649B2 (https=)
CA (1) CA3153359A1 (https=)
CL (1) CL2022000531A1 (https=)
CO (1) CO2022003078A2 (https=)
CR (1) CR20220138A (https=)
EC (1) ECSP22026797A (https=)
IL (1) IL290792B1 (https=)
MX (1) MX2022002728A (https=)
PE (1) PE20221443A1 (https=)
PH (1) PH12022550505A1 (https=)
TW (1) TWI861205B (https=)
WO (1) WO2021046549A1 (https=)
ZA (1) ZA202203681B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210079278A (ko) 2018-09-06 2021-06-29 시다라 세라퓨틱스, 인코포레이티드 바이러스 감염의 치료를 위한 조성물 및 방법
TWI861205B (zh) 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法
AU2021210987A1 (en) * 2020-01-24 2022-08-04 Regeneron Pharmaceuticals, Inc. Protein-antiviral compound conjugates
US20230364251A1 (en) 2020-08-06 2023-11-16 Cidara Therapeutics, Inc. Methods for the synthesis of protein-drug conjugates
EP4192510A1 (en) 2020-08-06 2023-06-14 Cidara Therapeutics, Inc. Methods for the synthesis of protein-drug conjugates
US20240285786A1 (en) 2021-03-11 2024-08-29 Cidara Therapeutics, Inc. Protein-drug conjugates for antiviral therapy
WO2023125806A1 (zh) * 2021-12-30 2023-07-06 苏州爱科百发生物医药技术有限公司 用于预防和治疗病毒感染的偶联物及其用途
EP4551563A2 (en) * 2022-07-05 2025-05-14 Cidara Therapeutics, Inc. Fc conjugates including an inhibitor of cd73 and uses thereof
WO2025002421A1 (zh) 2023-06-29 2025-01-02 上海爱科百发生物医药技术股份有限公司 用于预防和治疗病毒感染的偶联物及其用途
WO2025064869A2 (en) * 2023-09-20 2025-03-27 Cidara Therapeutics, Inc. Compositions and methods for the treatment of cancer
WO2025119337A1 (zh) * 2023-12-08 2025-06-12 苏州拓界医药有限公司 一种抗病毒偶联物
WO2025157263A1 (zh) * 2024-01-26 2025-07-31 浙江养生堂天然药物研究所有限公司 偶联物及其制备方法和用途
WO2025230581A1 (en) * 2024-05-02 2025-11-06 Cidara Therapeutics, Inc. Fc conjugates and uses thereof
WO2026055183A1 (en) * 2024-09-03 2026-03-12 Vir Biotechnology, Inc Antiviral compositions and methods of using the same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335368A (en) 1996-11-14 2001-08-31 Biota Scient Management Macromolecular compound with one or more neuraminidase binders, binds to the active site of influenza virus neuraminidase
US6495580B1 (en) 1998-01-29 2002-12-17 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AUPP913999A0 (en) 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
SG122814A1 (en) 1999-06-28 2006-06-29 Janssen Pharmaceutica Nv Respiratory syncytial virus replication inhibitors
AUPR001000A0 (en) 2000-09-08 2000-10-05 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
AUPR879701A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
CA2495266A1 (en) 2002-08-09 2004-02-19 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
AU2006279304A1 (en) 2005-08-19 2007-02-22 Endocyte, Inc. Multi-drug ligand conjugates
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
EP2395992A2 (en) 2009-02-10 2011-12-21 The Scripps Research Institute Chemically programmed vaccination
CN103068378B (zh) 2010-05-10 2016-07-06 中央研究院 具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法
MA34392B1 (fr) 2010-06-24 2013-07-03 Gilead Sciences Inc Pyrimidines en tant qu'agents antiviraux
RS55609B1 (sr) 2011-04-13 2017-06-30 Bristol Myers Squibb Co Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
US9834597B2 (en) 2012-09-21 2017-12-05 The Regents Of The University Of California Modified FC polypeptides, FC conjugates, and methods of use thereof
BR112015008325B1 (pt) 2012-10-16 2022-01-25 Janssen Sciences Ireland Uc Compostos antivirais contra o rsv, seu uso e composição farmacêutica que os compreende
EP3385277A1 (en) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22 polypeptides and il-22 fc fusion proteins and methods of use
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
JP6211195B2 (ja) 2013-08-12 2017-10-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 呼吸器合胞体ウイルス感染症の処置および予防のための新規アザ−オキソ−インドール
TWI671299B (zh) 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為rsv抗病毒化合物之螺脲化合物
WO2017046625A1 (en) 2015-06-25 2017-03-23 Cube Biotech Gmbh New chelators for affinity purification of recombinant proteins
WO2018006063A1 (en) 2016-07-01 2018-01-04 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
US20230190950A1 (en) * 2017-01-06 2023-06-22 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
KR20210079278A (ko) * 2018-09-06 2021-06-29 시다라 세라퓨틱스, 인코포레이티드 바이러스 감염의 치료를 위한 조성물 및 방법
EP3982994A4 (en) 2019-06-13 2023-10-04 Cidara Therapeutics, Inc. Compositions and methods for the treatment of respiratory syncytial virus
AU2020291469A1 (en) 2019-06-13 2022-02-10 Cidara Therapeutics, Inc. Compositions and methods for the treatment of human immunodeficiency virus
TWI861205B (zh) 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法
US20240285786A1 (en) * 2021-03-11 2024-08-29 Cidara Therapeutics, Inc. Protein-drug conjugates for antiviral therapy

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021016375A2 (https=)
BR102021016200A2 (https=)
BR112021013417A2 (https=)
BR112023008622A2 (https=)
BR102020022457A2 (https=)
BR102020021699A2 (https=)
BR102020019899A2 (https=)
BR102020016437A2 (https=)
CN305531253S (https=)